Contemporary Post Surgical Management of Differentiated Thyroid Carcinoma

Cooper, 2009, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer, Thyroid, 19, 1167, 10.1089/thy.2009.0110

Tuttle, 2007, Papillary thyroid cancer: monitoring and therapy, Endocrinol Metab Clin North Am, 36, 753, 10.1016/j.ecl.2007.04.004

Tuttle, 2008, Medical management of thyroid cancer: a risk adapted approach, J Surg Oncol, 97, 712, 10.1002/jso.21010

Tuttle, 2008, Follow up approaches in thyroid cancer: a risk adapted paradigm, Endocrinol Metab Clin North Am, 37, 419, 10.1016/j.ecl.2008.02.008

Liu, 2006, Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity, Cancer, 107, 1255, 10.1002/cncr.22138

Kondo, 2006, Pathogenetic mechanisms in thyroid follicular-cell neoplasia, Nat Rev Cancer, 6, 292, 10.1038/nrc1836

Baloch, 2001, Prognostic factors in well-differentiated follicular-derived carcinoma and medullary thyroid carcinoma, Thyroid, 11, 637, 10.1089/105072501750362709

Nikiforova, 2008, Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis, Expert Rev Mol Diagn, 8, 83, 10.1586/14737159.8.1.83

Ward, 2007, Identifying a risk profile for thyroid cancer, Arq Bras Endocrinol Metabol, 51, 713, 10.1590/S0004-27302007000500008

Kebebew, 2007, The prevalence and prognostic value of BRAF mutation in thyroid cancer, Ann Surg, 246, 466, 10.1097/SLA.0b013e318148563d

Lupi, 2007, Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma, J Clin Endocrinol Metab, 92, 4085, 10.1210/jc.2007-1179

Robbins, 2006, Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning, J Clin Endocrinol Metab, 91, 498, 10.1210/jc.2005-1534

Tuttle, 2007, Investigational therapies for metastatic thyroid carcinoma, J Natl Compr Canc Netw, 5, 641, 10.6004/jnccn.2007.0055

Mazzaferri, 2001, Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer, J Clin Endocrinol Metab, 86, 1447, 10.1210/jcem.86.4.7407

Brierley, 1997, A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example, Cancer, 79, 2414, 10.1002/(SICI)1097-0142(19970615)79:12<2414::AID-CNCR18>3.0.CO;2-U

2002

DeGroot, 1990, Natural history, treatment, and course of papillary thyroid carcinoma, J Clin Endocrinol Metab, 71, 414, 10.1210/jcem-71-2-414

Pilli, 2007, A comparison of 1850 (50mCi) and 3700MBq (100mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer, J Clin Endocrinol Metab, 92, 3542, 10.1210/jc.2007-0225

Mazzaferri, 1994, Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer, Am J Med, 97, 418, 10.1016/0002-9343(94)90321-2

Durante, 2006, Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy, J Clin Endocrinol Metab, 91, 2892, 10.1210/jc.2005-2838

Sawka, 2008, An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer, Endocrinol Metab Clin North Am, 37, 457, 10.1016/j.ecl.2008.02.007

Hundahl, 1998, A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995, Cancer, 83, 2638, 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1

Sanders, 1998, Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment, Arch Surg, 133, 419, 10.1001/archsurg.133.4.419

Kim, 2004, Predicting outcome and directing therapy for papillary thyroid carcinoma, Arch Surg, 139, 390, 10.1001/archsurg.139.4.390

Lundgren, 2007, Influence of surgical and postoperative treatment on survival in differentiated thyroid cancer, Br J Surg, 94, 571, 10.1002/bjs.5635

Grewal, 2009, Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation, J Nucl Med, 50, 1605, 10.2967/jnumed.108.061382

Walter, 2007, The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study, J Nucl Med, 48, 1620, 10.2967/jnumed.107.042192

Brown, 2008, The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer, J Clin Endocrinol Metab, 93, 504, 10.1210/jc.2007-1154

Sawka, 2009, Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis, Thyroid, 19, 451, 10.1089/thy.2008.0392

Molinaro, 2009, Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation, Thyroid, 19, 1035, 10.1089/thy.2008.0430

Edmonds, 1977, Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine, Br J Radiol, 50, 799, 10.1259/0007-1285-50-599-799

Pacini, 2006, Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study, J Clin Endocrinol Metab, 91, 926, 10.1210/jc.2005-1651

Chianelli, 2009, Low-activity (2.0GBq; 54mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients, Eur J Endocrinol, 160, 431, 10.1530/EJE-08-0669

Tuttle, 2010, Radioactive iodine administered for thyroid remnant ablation following recombinant human TSH preparation also has an important adjuvant therapy function, Thyroid, 20, 1, 10.1089/thy.2009.0401

Tuttle, 2008, Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal, J Nucl Med, 49, 764, 10.2967/jnumed.107.049072

Fatourechi, 2000, Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?, Thyroid, 10, 573, 10.1089/thy.2000.10.573

Souza Rosario, 2004, Post I-131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution?, Clin Nucl Med, 29, 795, 10.1097/00003072-200412000-00005

Biondi, 2005, Thyroid-hormone therapy and thyroid cancer: a reassessment, Nat Clin Pract Endocrinol Metab, 1, 32, 10.1038/ncpendmet0020

McGriff, 2002, Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer, Ann Med, 34, 554, 10.1080/078538902321117760

Biondi, 2010, Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer, Thyroid, 20, 135, 10.1089/thy.2009.0311

Cooper, 1998, Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry, Thyroid, 8, 737, 10.1089/thy.1998.8.737

Wang, 2001, Resistance of [18F]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine, Thyroid, 11, 1169, 10.1089/10507250152741028

Hyer, 2007, Salivary gland toxicity after radioiodine therapy for thyroid cancer, Clin Oncol (R Coll Radiol), 19, 83, 10.1016/j.clon.2006.11.005

Kloos, 2002, Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma, J Clin Endocrinol Metab, 87, 5817, 10.1210/jc.2002-020210

Vini, 2002, Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer, Postgrad Med J, 78, 92, 10.1136/pmj.78.916.92

Dottorini, 1995, Assessment of female fertility and carcinogenesis after I-131 therapy for differentiated thyroid-carcinoma, J Nucl Med, 36, 21

Sawka, 2008, A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors, Clin Endocrinol, 68, 610, 10.1111/j.1365-2265.2007.03081.x

Ceccarelli, 2001, 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study, J Clin Endocrinol Metab, 86, 3512, 10.1210/jcem.86.8.7719

Hyer, 2002, Testicular dose and fertility in men following I-131 therapy for thyroid cancer, Clin Endocrinol, 56, 755, 10.1046/j.1365-2265.2002.t01-1-01545.x

Lushbaugh, 1976, The effects of gonadal irradiation in clinical radiation therapy: a review, Cancer, 37, 1111, 10.1002/1097-0142(197602)37:2+<1111::AID-CNCR2820370821>3.0.CO;2-E